Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.
about
Deep molecular responses for treatment-free remission in chronic myeloid leukemiaConsiderations for accurate gene expression measurement by reverse transcription quantitative PCR when analysing clinical samplesMeasurable residual disease testing in acute myeloid leukaemia.A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCRLaboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase.A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.Detection of a rare BCR-ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS)Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.BCR-ABL1 kinase domain mutations: methodology and clinical evaluation.Molecular monitoring.Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization.Measurement of BCR-ABL1 by RT-qPCR in chronic myeloid leukaemia: findings from an International EQA Programme.The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor eraMonitoring of response to therapy with imatinib mesylate in Chronic Myeloid Leukemia in chronic phase (CML-CP).Mesoscale blood cell sedimentation for processing millilitre sample volumes.PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase.Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.Laboratory Monitoring of Chronic Myeloid Leukemia in Patients on Tyrosine Kinase Inhibitors.Development of a cost-effective 'duplexed' real-time PCR assay for minimal residual disease monitoring of chronic myeloid leukemia using locked nucleic acid probes.A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects.Comment on: Technical Issues Behind Molecular Monitoring in Chronic Myeloid Leukemia.The benefit of quality control charts (QCC) for routine quantitative BCR-ABL1 monitoring in chronic myeloid leukemia.Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK
P2860
Q26745594-E2E61819-C39F-4F2C-ACD5-D024564A1CE8Q26863503-52F6665E-A81C-4B16-A3D9-8B3DF92515ECQ30234914-BD1468AD-178C-4013-836B-34D3D296D64DQ35059443-B5171A64-F5B1-4313-9071-15124DC0117CQ35603605-A0007FFE-3E87-4570-8A47-F58D2E21BC99Q36184500-4E957F5B-EF91-40C9-B414-537F0FD98BEBQ36302377-B67CCF73-52D9-48E1-804A-D7DB265830F2Q36342992-CA0410A0-5CEA-48DC-A873-3A66A32DCFC0Q37696776-0C27FCEB-B9BF-43BA-B220-95CE757BFAA7Q37974490-CFB25944-60B9-4C49-A181-303802A250CBQ38176284-A9B84B3D-7A6A-4548-BADF-272D3D228F8EQ38392702-DB26B6F5-C721-41BB-B9AB-92ECAB334B0FQ38907096-98E050C1-029C-4846-A752-D694802AA6CAQ42588031-91C3B819-0D58-4542-B05F-18F534452B68Q42982577-B68CAE63-5265-4C48-8DC2-C9548A34EABEQ51487449-8F81B20E-45D6-43C9-BF41-9C1CFA25FA92Q53017093-8F5FCF75-6AFC-473F-B698-BBEE453C6645Q53640330-F60A508A-CE47-47B3-93CA-D68F3961C385Q54117334-BDE750F3-ECD0-4A2C-AF60-6D924BD4573AQ54148021-DB19F923-6953-4394-B9C1-A983BA13A720Q54240000-5BDB1D92-B643-4194-996F-BAE0B1240835Q54397703-B1490D44-490B-4956-AE5F-686B7AA2F3C3Q55052030-F1B00DFF-0D14-4BC5-B732-010196ACD6D1Q55092219-6E6E504B-489C-438E-8612-F1733B0A8718Q58455606-B4FC2DD8-F691-4B59-9EDF-97ACAD2D5DE7
P2860
Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.
@en
Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.
@nl
type
label
Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.
@en
Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.
@nl
prefLabel
Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.
@en
Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.
@nl
P2093
P2860
P1476
Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.
@en
P2093
Abida Awan
Alexandra E Irvine
Anna Schuh
Anne Sproul
Aytug Kizilors
Benedict J Milner
Caroline Wickham
David Gonzalez de Castro
David Grimwade
P2860
P304
P356
10.1111/J.1365-2141.2011.08603.X
P407
P577
2011-03-08T00:00:00Z